Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system (CNS) disorders. The company’s novel pipeline is based on Nobel Prize winning research and leverages groundbreaking science to address some of the most urgent diseases in CNS and beyond.
The company has four novel and differentiated drug development programs. OLINVYK® is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com.
The company has three investigational drug candidates, including TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. The company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating diabetic neuropathic pain, epilepsy, and other CNS disorders.
TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in preclinical models
$12 million financing completed, including non-dilutive $2 million tranche and $10 million reduction in liabilities associated with existing ex-US royalty financing.
No comments:
Post a Comment